Key result
Ximelagatran offers an alternative to warfarin for nonvalvular atrial fibrillation without coagulation monitoring, though liver enzyme elevation may limit its long-term clinical utility.
Why the study?
Does ximelagatran provide a safe and effective alternative to warfarin in patients with nonvalvular atrial fibrillation?
Does ximelagatran provide a safe and effective alternative to warfarin in patients with nonvalvular atrial fibrillation?
Ximelagatran is a promising direct thrombin inhibitor for nonvalvular atrial fibrillation that avoids the need for routine coagulation monitoring, although hepatotoxicity remains a significant clinical concern.
Answers are grounded in this paper and cite their sources.
Caution advised for nonvalvular AF use; leaves open hepatotoxicity mitigation in future direct thrombin inhibitor development.
Ximelagatran, an emerging new direct, oral, fixed-dose thrombin inhibitor may offer an attractive alternate to warfarin for patients with nonvalvular atrial fibrillation. The lack of drug-to-drug interactions and need for coagulation monitoring parameters such as international normalized ratio and a short half-life make therapeutic control and withdrawal in the event of bleeding easier. The side-effect profile, including elevation of liver enzymes, may temper the clinical utility of long-term use ximelagatran.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2005) conducted a review in Nonvalvular atrial fibrillation. Ximelagatran vs. warfarin was evaluated. Ximelagatran offers an alternative to warfarin for nonvalvular atrial fibrillation without coagulation monitoring, though liver enzyme elevation may limit its long-term clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: